Combination Therapy for Pediatric Asthma Patients

Trial Objective

Our researchers are trying to determine if a combination of fluticasone furoate (FF) and vilanterol (VI) is more effective than FF alone in improving lung function and symptoms such as coughing, wheezing, chest tightness and breathlessness in pediatric asthma patients.

Combination Therapy for Pediatric Asthma Patients

FF (which is approved for treatment of asthma) is typically used to treat asthma in adults. This study is adding the use of VI (which is not currently approved for the treatment of asthma). The study also will determine the safety of the combination of FF and VI. Some participants will receive FF and VI, some others will receive FF alone. There is no placebo for this study.


This trial is active and currently recruiting.

How to Participate

For more information, contact Michael White or Dee Sundstrom at 303.398.1470 or complete the form below.

Who Can Participate

Children and teens ages 5 to 17 who have uncontrolled asthma and are receiving stable asthma therapy.

Estimated Time Commitment

7 visits up to 29 weeks

(1) a four-week period during when participants will receive a study medication called Fluticasone Propionate (FP), (2) a 24-week treatment period when participants will not know if they are receiving the study medication.

Trial Location

National Jewish Main Campus, Denver, CO



Trial Sponsors

GlaxoSmithKline (GSK)




Any Gender

Principal Investigators

Request More Information